vs

Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $37.2M, roughly 1.2× Organogenesis Holdings Inc.). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs -57.1%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs -46.5%).

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

DX vs ORGO — Head-to-Head

Bigger by revenue
DX
DX
1.2× larger
DX
$43.5M
$37.2M
ORGO
Growing faster (revenue YoY)
DX
DX
+588.4% gap
DX
531.3%
-57.1%
ORGO
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
DX
DX
ORGO
ORGO
Revenue
$43.5M
$37.2M
Net Profit
Gross Margin
30.8%
Operating Margin
-185.1%
Net Margin
Revenue YoY
531.3%
-57.1%
Net Profit YoY
EPS (diluted)
$1.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DX
DX
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$43.5M
$225.6M
Q3 25
$30.6M
$150.9M
Q2 25
$23.1M
$101.0M
Q1 25
$17.1M
$86.7M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$130.2M
Net Profit
DX
DX
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$150.4M
$21.6M
Q2 25
$-13.6M
$-9.4M
Q1 25
$-3.1M
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$-17.0M
Gross Margin
DX
DX
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
DX
DX
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Net Margin
DX
DX
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
491.3%
14.3%
Q2 25
-58.8%
-9.3%
Q1 25
-18.0%
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
EPS (diluted)
DX
DX
ORGO
ORGO
Q1 26
Q4 25
$1.59
$0.31
Q3 25
$1.08
$0.11
Q2 25
$-0.14
$-0.10
Q1 25
$-0.06
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DX
DX
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$531.0M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.5B
Total Assets
$17.3B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DX
DX
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$531.0M
$93.7M
Q3 25
$491.0M
$63.7M
Q2 25
$387.5M
$73.1M
Q1 25
$327.4M
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
DX
DX
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
DX
DX
ORGO
ORGO
Q1 26
Q4 25
$2.5B
$300.1M
Q3 25
$2.0B
$255.1M
Q2 25
$1.6B
$233.2M
Q1 25
$1.4B
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Total Assets
DX
DX
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$17.3B
$598.7M
Q3 25
$14.2B
$509.8M
Q2 25
$11.3B
$461.1M
Q1 25
$9.0B
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Debt / Equity
DX
DX
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DX
DX
ORGO
ORGO
Operating Cash FlowLast quarter
$120.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DX
DX
ORGO
ORGO
Q1 26
Q4 25
$120.8M
$39.4M
Q3 25
$68.3M
$3.1M
Q2 25
$31.9M
$-32.9M
Q1 25
$6.4M
$-19.9M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$4.7M
Free Cash Flow
DX
DX
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
DX
DX
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
DX
DX
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
DX
DX
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.45×
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons